Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 24Terminated 7Recruiting 3Unknown 2Active not recruiting 2Withdrawn 1Not yet recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Rectal Neoplasms 1Neoplasm Metastasis 1Colorectal Neoplasms 1

Interventions

Radiotherapy 91pembrolizumab 88Cyclophosphamide 84Gemcitabine 70Cisplatin 70Magnetic Resonance Spectroscopy 65Carboplatin 60Radiosurgery 55Paclitaxel 55Nivolumab 48Dexamethasone 45Bevacizumab 42Biopsy 41Fluorouracil 39durvalumab 37Surveys and Questionnaires 36Docetaxel 36fludarabine 35Doxorubicin 35Radiation 33Oxaliplatin 33Capecitabine 33Rituximab 32fludarabine phosphate 31Leucovorin 31Cytarabine 30Melphalan 29Etoposide 28Pemetrexed 27Irinotecan 27

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × OTHER × Pharmacogenomic Testing × Clear all
NCT00936832 2022-08-30

Sunitinib Malate and Combination Chemotherapy as Front-Line Therapy in Treating Patients With Metastatic Rectal Cancer That Cannot Be Removed by Surgery

Federation Francophone de Cancerologie Digestive

Phase 2 Withdrawn
Gastrointestinal

Neoplasm Metastasis, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡